167 related articles for article (PubMed ID: 21562972)
1. Clinical experience with recombinant molecules for allergy vaccination.
Cromwell O; Niederberger V; Horak F; Fiebig H
Curr Top Microbiol Immunol; 2011; 352():27-42. PubMed ID: 21562972
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials with recombinant allergens--three perspectives: industry.
Narkus A; Kniest F; Menzel A; Meyer H; Sprung V
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():270-5; discussion 275-8. PubMed ID: 20799471
[No Abstract] [Full Text] [Related]
3. Ultra-short-course booster allergen immunotherapy.
Pfaar O; Pieper-Fürst U; Mösges R
Immunotherapy; 2018 Jun; 10(7):525-528. PubMed ID: 29562789
[No Abstract] [Full Text] [Related]
4. Sublingual immunotherapy: allergen specific or placebo effect?
Kette F; Smith W
J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261
[No Abstract] [Full Text] [Related]
5. Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy.
Scurlock AM
Clin Rev Allergy Immunol; 2018 Oct; 55(2):139-152. PubMed ID: 29656306
[TBL] [Abstract][Full Text] [Related]
6. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
8. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Larenas-Linnemann D
Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
[TBL] [Abstract][Full Text] [Related]
9. Allergen immunotherapy for birch-apple syndrome: what do we know?
Incorvaia C; Ridolo E; Mauro M; Russello M; Pastorello E
Immunotherapy; 2017 Nov; 9(15):1271-1278. PubMed ID: 29130794
[TBL] [Abstract][Full Text] [Related]
10. Serum immunoglobulin E reactivity to cross-reacting panallergen components in north-eastern Poland patients pollen sensitized.
Kowal K; Pampuch A; Sacharzewska E; Swiebocka E; Siergiejko Z; Siergiejko G; Chruszcz M; DuBuske L
Allergy Asthma Proc; 2020 May; 41(3):183-191. PubMed ID: 32375962
[No Abstract] [Full Text] [Related]
11. Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy.
Garmatiuk T; Swoboda I; Twardosz-Kropfmüller A; Dall'Antonia F; Keller W; Singh MB; Bhalla PL; Okada T; Toriyama K; Weber M; Ghannadan M; Sperr WR; Blatt K; Valent P; Klein B; Niederberger V; Curin M; Balic N; Spitzauer S; Valenta R
Immunobiology; 2013 Sep; 218(9):1155-1165. PubMed ID: 23790497
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
13. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
14. Improving pollen immunotherapy: minor allergens and panallergens.
Moreno-Aguilar C
Allergol Immunopathol (Madr); 2008; 36(1):26-30. PubMed ID: 18261430
[TBL] [Abstract][Full Text] [Related]
15. Epicutaneous immunotherapy.
Scheurer S; Toda M
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():25-29. PubMed ID: 29108765
[No Abstract] [Full Text] [Related]
16. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen.
Martínez-Cañavate Burgos A; Torres-Borrego J; Molina Terán AB; Corzo JL; García BE; Rodríguez Pacheco R; Moreno Aguilar C; Dávila I
Pediatr Allergy Immunol; 2018 Jun; 29(4):369-374. PubMed ID: 29369414
[TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
[TBL] [Abstract][Full Text] [Related]
18. Detection of pan-allergens in commercial pollen extracts for allergen immunotherapy.
Asero R; Mistrello G; Amato S
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):180-5. PubMed ID: 27238577
[TBL] [Abstract][Full Text] [Related]
19. Allergen-specific immunotherapy with recombinant allergens.
Pauli G; Malling HJ
Curr Top Microbiol Immunol; 2011; 352():43-54. PubMed ID: 21404096
[TBL] [Abstract][Full Text] [Related]
20. A molecular diagnostic algorithm to guide pollen immunotherapy in southern Europe: towards component-resolved management of allergic diseases.
Douladiris N; Savvatianos S; Roumpedaki I; Skevaki C; Mitsias D; Papadopoulos NG
Int Arch Allergy Immunol; 2013; 162(2):163-72. PubMed ID: 23921568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
